COVID-19 Lesson: India Earmarks $1.3bn To Reduce Dependence On China
Lopinavir, Ritonavir On List Of 53 Incentivized APIs
In a bid to ensure long-term medicines security, the Indian government has earmarked $1.32bn to promote domestic production of 53 APIs, including lopinavir and ritonavir currently being evaluated to treat COVID-19 cases, as well as antibiotics, for which India is highly dependent on China.
You may also be interested in...
Covering nearly a third of the world’s population and roughly 30% of global GDP, the newly signed Regional Comprehensive Economic Partnership is set to accelerate trade within the Asia Pacific region. But India’s last-minute withdrawal means China may dominate the agenda going forward.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products - they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.